Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

The epidermal growth factor receptor (EGFR), which participates in signalling pathways that are deregulated in cancer cells, is frequently mutated in colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We evaluated the efficacy of cetuximab in weekly combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenzi, B, Santini, D, Rabitti, C, Coppola, R, Beomonte Zobel, B, Trodella, L, Tonini, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361373/
https://www.ncbi.nlm.nih.gov/pubmed/16508634
http://dx.doi.org/10.1038/sj.bjc.6603018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361373/
https://www.ncbi.nlm.nih.gov/pubmed/16508634
http://dx.doi.org/10.1038/sj.bjc.6603018

Ejemplares similares